Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNX NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$83.500.0%$37.67$25.83▼$83.63$8.80B0.232.00 million shs13.95 million shsVRTXVertex Pharmaceuticals$500.07-4.2%$453.10$362.50▼$533.67$127.04B0.291.47 million shs1.13 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+98.74%+123.22%+153.74%+109.03%+187.44%VRTXVertex Pharmaceuticals-1.39%+5.14%+16.88%+17.65%+13.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$83.500.0%$37.67$25.83▼$83.63$8.80B0.232.00 million shs13.95 million shsVRTXVertex Pharmaceuticals$500.07-4.2%$453.10$362.50▼$533.67$127.04B0.291.47 million shs1.13 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+98.74%+123.22%+153.74%+109.03%+187.44%VRTXVertex Pharmaceuticals-1.39%+5.14%+16.88%+17.65%+13.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.40Hold$78.27-6.29% DownsideVRTXVertex Pharmaceuticals 2.84Moderate Buy$557.096.67% UpsideCurrent Analyst Ratings BreakdownLatest VRTX and CRNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2026VRTXVertex Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$543.00 ➝ $570.007/7/2026CRNXCrinetics Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$85.007/7/2026CRNXCrinetics Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$55.00 ➝ $85.007/7/2026CRNXCrinetics Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform7/7/2026CRNXCrinetics Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$62.00 ➝ $85.007/7/2026CRNXCrinetics Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$81.00 ➝ $85.007/7/2026CRNXCrinetics Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Hold7/2/2026CRNXCrinetics Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$55.006/30/2026VRTXVertex Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)(Data available from 7/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$7.70M1,143.82N/AN/A$9.71 per share8.60VRTXVertex Pharmaceuticals$12.00B11.04$17.33 per share30.13$73.57 per share7.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$465.32M-$5.13N/AN/AN/A-2,747.18%-43.96%-39.61%8/4/2026 (Estimated)VRTXVertex Pharmaceuticals$3.95B$16.8630.9827.542.2735.51%23.86%17.13%8/3/2026 (Estimated)Latest VRTX and CRNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026CRNXCrinetics Pharmaceuticals-$1.23N/AN/AN/A$14.87 millionN/A8/3/2026Q2 2026VRTXVertex Pharmaceuticals$4.73N/AN/AN/A$3.22 billionN/A5/7/2026Q1 2026CRNXCrinetics Pharmaceuticals-$1.22-$1.23-$0.01-$1.23$8.51 million$10.73 million5/4/2026Q1 2026VRTXVertex Pharmaceuticals$4.24$4.47+$0.23$4.02$2.99 billion$2.99 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A18.6018.56VRTXVertex PharmaceuticalsN/A3.022.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals3.80%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals210105.44 million101.43 millionOptionableVRTXVertex Pharmaceuticals6,400253.80 million253.30 millionOptionableVRTX and CRNX HeadlinesRecent News About These CompaniesCrinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX2 hours ago | businesswire.comCiti Remains a Buy on Vertex Pharmaceuticals (VRTX)2 hours ago | theglobeandmail.comVertex’s Crinetics Deal Balances Growth with Integration Risk...July 8 at 9:05 AM | marketbeat.comViking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics DealJuly 8 at 7:27 AM | finance.yahoo.comBiotech Stocks Worth Watching - July 7thJuly 8 at 6:12 AM | americanbankingnews.comSwedbank AB Has $121.26 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTXJuly 8 at 5:43 AM | marketbeat.comOurania Tatsis Sells 1,500 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) StockJuly 8 at 5:36 AM | insidertrades.comVertex Pharmaceuticals (NASDAQ:VRTX) Hits New 52-Week High - Time to Buy?July 8 at 4:59 AM | marketbeat.comVertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.July 8 at 3:28 AM | fool.comWhy Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today?July 8 at 1:41 AM | stocktwits.comSVKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?July 8 at 1:41 AM | stocktwits.comSVertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.July 7 at 11:00 PM | fool.comVertex to Announce Second Quarter 2026 Financial Results on August 3rdJuly 7 at 8:40 PM | uk.finance.yahoo.comVertex (VRTX) Is Buying Crinetics For $10 Billion And Entering EndocrinologyJuly 7 at 8:40 PM | finance.yahoo.comVertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to NoteJuly 7 at 8:40 PM | finance.yahoo.comVertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to NoteJuly 7 at 7:01 PM | zacks.comOurania Tatsis Sells 1,500 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) StockJuly 7 at 5:06 PM | marketbeat.comVertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells $799,779.00 in StockJuly 7 at 5:06 PM | marketbeat.comVertex sees over $5 billion peak sales potential from Crinetics assetsJuly 7 at 3:40 PM | msn.comTop Midday GainersJuly 7 at 3:40 PM | finance.yahoo.comVertex Pays $10 Billion to Enter Rare Endocrine DiseaseJuly 7 at 3:40 PM | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 2026Vertex’s Crinetics Deal Balances Growth with Integration RiskBy Chris Markoch | July 8, 2026VRTX and CRNX Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$83.50 -0.04 (-0.04%) As of 03:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Vertex Pharmaceuticals NASDAQ:VRTX$500.07 -22.18 (-4.25%) As of 03:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Exxon Could Be the Market's Next Big Comeback Stock Why Penguin Solutions May Be the Smartest AI Infrastructure Stock The Market Just Got Shaken—These 3 ETFs May Come Out Stronger Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns A Market Panic Just Discounted the AI Highway's Tollbooth Vertex’s Crinetics Deal Balances Growth with Integration Risk Apple and Broadcom Forge a Decade-Long Silicon Fortress These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
